Nadixa (Nadifloxacin)

Nadifloxacin, the active ingredient in Nadixa, is a fluoroquinolone antibiotic presented as a topical formulation for topical use. It treats bacterial skin infections such as acne vulgaris and impetigo by inhibiting bacterial DNA replication, providing a targeted antimicrobial effect on the skin.

GNH USA supplies Nadixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The company follows stringent manufacturing standards and provides reliable logistics for timely delivery.

Nadixa (nadifloxacin) is indicated for dermatological conditions caused by susceptible bacteria, acting primarily on the skin surface.

Acne vulgaris: reduces inflammatory lesions and bacterial colonisation on the face and trunk. Impetigo: eradicates Staphylococcus aureus and Streptococcus pyogenes, promoting rapid resolution of crusted lesions. Other bacterial skin infections (e.g., folliculitis, infected eczema): provides topical antibacterial activity to control infection and prevent spread.

Topical application of Nadixa may be associated with local and, rarely, systemic adverse reactions.

Common Side Effects: - Application site irritation: mild burning or stinging sensation. - Pruritus: itching at the site of application. - Dryness or scaling of the skin. - Redness (erythema) around the treated area.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face or throat. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: widespread skin blistering and detachment. - Photosensitivity: heightened skin reaction to sunlight leading to severe sunburn.

When prescribing Nadixa, clinicians should observe the following precautions to ensure safe and effective use.

- Duration of therapy: limit use to the prescribed period, typically not exceeding two weeks, to reduce resistance risk. - Surface area: avoid application to large body surface areas (>10% of total body surface) without medical supervision. - Ocular exposure: do not apply near eyes; if contact occurs, rinse thoroughly with water. - Fluoroquinolone hypersensitivity: contraindicated in patients with known allergy to nadifloxacin or other fluoroquinolones. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at below 25°C: keep in original packaging, protect from moisture and direct light.

Nadixa may interact with other medicines or substances; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Systemic fluoroquinolones: concurrent use may increase risk of additive fluoroquinolone toxicity. - Photosensitising agents (e.g., tetracyclines, sulfonamides): may amplify photosensitivity reactions. - Topical corticosteroids: can mask signs of infection and diminish antibacterial effect.

Moderate Interactions (Monitor Closely): - Other topical antibiotics (e.g., mupirocin): may increase local irritation. - Antiseptic dressings containing aluminium or silver: could reduce drug absorption. - Herbal or cosmetic skin products: potential for additive irritation or allergic responses.